- Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy Fierce Biotech
- We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress statnews.com
- Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug Yahoo Finance
- Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths The New York Times
- 5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis BioPharma Dive
Source link
